Clinical trials: Amyloidosis Transthyretin
Transthyretin Amyloid Cardiomyopathy
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that…
- Trial name
- NCT07690436
- Where
- 20 sites in United States, Germany and 3 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Cardiac Amyloidosis, Chest Pain
CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis
The objective of this observational, prospective study is to determine the prevalence of Cardiac Amyloidosis (CA) in males over the age of 65 who experience chest pain but show no signs of coronary artery disease (CAD).
- Trial name
- CHEST-CA (NCT07435168)
- Testing
- Screening thourgh examinations including bonescintigraphy
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN).
- Trial name
- NCT05071300
- Testing
- Eplontersen
- Where
- 33 sites in United States, Argentina and 11 more
- Volunteers
- 151 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Amyloidosis Cardiac, Aortic Stenosis, Severe
Analysis of Calcium Score of Severe Aortic Stenosis in Patients With and Without Cardiac Amyloidosis (CAUSATIVE Study)
The concomitant presence of cardiac amyloidosis (CA) in patients with aortic stenosis (AS) may challenge the estimation of stenosis degree.
- Trial name
- CAUSATIVE (NCT06066632)
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- University Hospital of Ferrara
Familial Amyloid Polyneuropathy
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
This study will examine whether Fx-1006A is effective in halting the progression of Familial Amyloid Polyneuropathy (FAP). Deposition of TTR amyloid is associated with a variety of human diseases.
- Trial name
- NCT00409175
- Testing
- Fx-1006A
- Where
- 10 sites in United States, Argentina and 7 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Amyloid Cardiomyopathy
Open-Label Study of AG10 in Patients With Cardiomyopathy
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of acoramidis administered on a background of stable heart failure therapy.
- Trial name
- NCT03536767
- Testing
- Acoramidis
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Hereditary Transthyretin Amyloidosis With Polyneuropthy
A Non-interventional Cohort Safety Study of Patients With hATTR-PN
This is a prospective, non-interventional, Long-term, multinational cohort safety study of patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN).
- Trial name
- NCT04850105
- Testing
- Data Collection
- Where
- 26 sites in Bulgaria, Cyprus and 6 more
- Volunteers
- 202 people
- Sponsor
- Akcea Therapeutics
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Thailand ATTR-CM Registry
The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally.
- Trial name
- NCT06338696
- Testing
- No intervention
- Where
- 8 sites in Thailand
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR)
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture.
- Conditions
- Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR), Hypertrophic Cardiomyopathy (HCM)
- Trial name
- Amylo (NCT01623245)
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Thibaud Damy
Amyloid, Cardiac Amyloidosis
Amyloidosis Incidence in High-Risk Cardiac Device Patients
This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation.
- Conditions
- Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis
- Trial name
- NCT06186167
- Testing
- Chest Wall Fat Tissue Collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Midwest Heart & Vascular Specialists
Amyloidosis, Amyloid Cardiomyopathy
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
- Conditions
- Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
- Trial name
- ATTRibute-CM (NCT03860935)
- Testing
- acoramidis
- Where
- 104 sites in United States, Australia and 16 more
- Volunteers
- 632 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Cardiac Amyloidosis
Individualized Exercise Training in Cardiac Amyloidosis
Numerous clinical trials have demonstrated that transthyretin (TTR)-directed medical therapies can reduce the rate of functional decline in patients with transthyretin cardiac amyloidosis (ATTR-CM).
- Trial name
- GET-FIT ATTR (NCT07835867)
- Testing
- Exercise Intervention, Physical Activity Handout
- Volunteers
- 60 people
- Sponsor
- Oregon Health and Science University
Transthyretin Amyloid Cardiomyopathy, Heart Failure
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
Clinical comparison of patients with transthyretin cardiac amyloidosis and patients with heart failure with reduced ejection fraction
- Trial name
- NCT05896904
- Testing
- Echocardiography
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Aarhus University Hospital Skejby
TTR-mediated Amyloidosis, Amyloidosis, Hereditary
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis.
- Conditions
- TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies
- Trial name
- NCT01960348
- Testing
- patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
- Where
- 52 sites in United States, Argentina and 19 more
- Volunteers
- 225 people
- Sponsor
- Alnylam Pharmaceuticals
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
- Trial name
- NCT04153149
- Testing
- Vutrisiran, Sterile Normal Saline (0.9% NaCl)
- Where
- 119 sites in United States, Argentina and 30 more
- Volunteers
- 655 people
- Sponsor
- Alnylam Pharmaceuticals
Amyloidosis in Transthyretin (TTR), Hereditary Amyloidosis, Transthyretin-Related
Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis.
Prospective study of development and validation of a questionnaire on quality of life in patients with Hereditary Amyloidosis The questionnaire development process will include 4 medical specialists experts in Transthyretin…
- Trial name
- NCT07080268
- Where
- Argentina
- Sponsor
- Hospital General de Niños Pedro de Elizalde
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2…
- Trial name
- NCT06073574
- Testing
- Cardiac MRI
- Where
- 11 sites in United States, Italy and 2 more
- Volunteers
- 160 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Amyloidosis
The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart
ATTRwt (also known as senile systemic, or senile cardiac amyloidosis) is a progressive heart disease, causing congestive heart failure.
- Trial name
- NCT02627820
- Testing
- Isis 420915/GSK 299872
- Sponsor
- Brigham and Women's Hospital
Heart Failure
CCM OPEN HF Registry
The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.
- Trial name
- CCM OPEN HF (NCT07112924)
- Where
- 30 sites in United States
- Volunteers
- 5,500 people
- Sponsor
- Impulse Dynamics
Amyloidosis, Paraproteinemias
Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging
Cardiac amyloidosis describes a process by which abnormally folded proteins infiltrate the heart tissue. Given the insidious nature of this disease process, diagnosis is often too late for a meaningful intervention.
- Conditions
- Amyloidosis, Paraproteinemias, Cardiomyopathies
- Trial name
- PICA-CMR (NCT02462213)
- Testing
- Amyloidosis, Cardiac Amyloidosis
- Where
- United States
- Sponsor
- University of Cincinnati